ProCE Banner Activity

Expert Insights on Targeted Therapies for Advanced Systemic Mastocytosis

Podcast Episodes
Learn how the experts incorporate KIT-targeted therapies into management of patients with advanced systemic mastocytosis in this multidisciplinary panel discussion featuring Dr Prithviraj Bose, Pharmacist Caitlin R. Rausch, and Nurse Practitioner Ilene A. Galinsky.

Released: March 10, 2022

Expiration: March 09, 2023

No longer available for credit.

Share

Faculty

Prithviraj Bose

Prithviraj Bose, MD

Professor
Department of Leukemia
UT MD Anderson Cancer Center
Houston, Texas

Ilene A. Galinsky

Ilene A. Galinsky, NP

Senior Research Program Adult Leukemia Nurse Practitioner
Department of Leukemia
Dana-Farber Cancer Institute/Brigham and Womens Hospital
Boston, Massachusetts

Caitlin R. Rausch

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Blueprint Medicines

Faculty Disclosure

Primary Author

Prithviraj Bose, MD

Professor
Department of Leukemia
UT MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD, has disclosed that he has received funds for research support from Astellas, Blueprint, Bristol-Myers Squibb, Cogent, Constellation, CTI BioPharma, Incyte, Ionis, Kartos, NS Pharma, Pfizer, and Promedior and consulting fees from AbbVie, Blueprint, Bristol-Myers Squibb, CTI BioPharma, Incyte, Karyopharm, Novartis, Pharma Essentia, and Sierra Oncology.

Ilene A. Galinsky, NP

Senior Research Program Adult Leukemia Nurse Practitioner
Department of Leukemia
Dana-Farber Cancer Institute/Brigham and Womens Hospital
Boston, Massachusetts

Ilene A. Galinsky, NP, has disclosed that she has received consulting fees from AbbVie, Jazz, Novartis, and Pfizer.

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
MD Anderson Cancer Center
Houston, Texas

Caitlin R. Rausch, PharmD, has no relevant conflicts of interest to report.